Wolverine Trading’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $40.4M | Buy |
102,100
+11,500
| +13% | +$4.81M | 0.03% | 381 |
|
|
2025
Q2 | $40M | Sell |
90,600
-1,600
| -2% | -$737K | 0.04% | 286 |
|
|
2025
Q1 | $45.4M | Buy |
92,200
+10,700
| +13% | +$4.99M | 0.05% | 226 |
|
|
2024
Q4 | $32.5M | Buy |
81,500
+14,800
| +22% | +$6.86M | 0.03% | 331 |
|
|
2024
Q3 | $30.9M | Sell |
66,700
-4,700
| -7% | -$2.26M | 0.03% | 316 |
|
|
2024
Q2 | $33.5M | Buy |
71,400
+3,600
| +5% | +$1.56M | 0.04% | 276 |
|
|
2024
Q1 | $28.3M | Buy |
67,800
+13,000
| +24% | +$5.5M | 0.03% | 321 |
|
|
2023
Q4 | $22.3M | Buy |
54,800
+23,600
| +76% | +$8.72M | 0.02% | 420 |
|
|
2023
Q3 | $10.8M | Buy |
31,200
+4,700
| +18% | +$1.64M | 0.01% | 596 |
|
|
2023
Q2 | $9.23M | Buy |
26,500
+6,500
| +33% | +$2.19M | 0.01% | 625 |
|
|
2023
Q1 | $6.24M | Sell |
20,000
-3,400
| -15% | -$1.02M | 0.01% | 732 |
|
|
2022
Q4 | $6.76M | Sell |
23,400
-7,800
| -25% | -$2.38M | 0.01% | 755 |
|
|
2022
Q3 | $9.13M | Buy |
31,200
+5,200
| +20% | +$1.5M | 0.01% | 601 |
|
|
2022
Q2 | $7.29M | Sell |
26,000
-5,000
| -16% | -$1.34M | 0.01% | 645 |
|
|
2022
Q1 | $7.95M | Sell |
31,000
-7,700
| -20% | -$1.83M | 0.01% | 804 |
|
|
2021
Q4 | $8.61M | Buy |
38,700
+11,500
| +42% | +$2.24M | 0.01% | 812 |
|
|
2021
Q3 | $4.96M | Sell |
27,200
-8,000
| -23% | -$1.56M | 0.01% | 1306 |
|
|
2021
Q2 | $6.93M | Buy |
35,200
+18,900
| +116% | +$3.95M | 0.01% | 899 |
|
|
2021
Q1 | $3.47M | Sell |
16,300
-28,800
| -64% | -$6.33M | 0.01% | 1406 |
|
|
2020
Q4 | $10.5M | Buy |
45,100
+5,000
| +12% | +$1.15M | 0.02% | 650 |
|
|
2020
Q3 | $10.8M | Sell |
40,100
-3,700
| -8% | -$1.02M | 0.03% | 502 |
|
|
2020
Q2 | $12.5M | Sell |
43,800
-31,900
| -42% | -$8.65M | 0.03% | 383 |
|
|
2020
Q1 | $17.6M | Sell |
75,700
-24,200
| -24% | -$5.55M | 0.05% | 257 |
|
|
2019
Q4 | $21.9M | Buy |
99,900
+19,500
| +24% | +$3.95M | 0.05% | 337 |
|
|
2019
Q3 | $13.4M | Sell |
80,400
-7,000
| -8% | -$1.24M | 0.04% | 407 |
|
|
2019
Q2 | $16M | Buy |
87,400
+17,800
| +26% | +$3.11M | 0.05% | 360 |
|
|
2019
Q1 | $12.8M | Buy |
69,600
+9,800
| +16% | +$1.81M | 0.04% | 408 |
|
|
2018
Q4 | $9.65M | Sell |
59,800
-19,800
| -25% | -$3.43M | 0.03% | 490 |
|
|
2018
Q3 | $15.3M | Buy |
79,600
+65,000
| +445% | +$11.6M | 0.03% | 385 |
|
|
2018
Q2 | $2.38M | Hold |
14,600
| – | – | 0.01% | 1446 |
|
|
2018
Q1 | $2.38M | Sell |
14,600
-13,600
| -48% | -$2.22M | 0.01% | 1446 |
|
|
2017
Q4 | $4.23M | Sell |
28,200
-29,000
| -51% | -$4.29M | 0.02% | 982 |
|
|
2017
Q3 | $8.7M | Buy |
+57,200
| New | +$8.61M | 0.03% | 480 |
|
|
2016
Q4 | – | Sell |
-60,800
| Closed | -$5.17M | – | 5246 |
|
|
2016
Q3 | $5.17M | Buy |
60,800
+5,100
| +9% | +$482K | 0.02% | 735 |
|
|
2016
Q2 | $4.74M | Buy |
+55,700
| New | +$4.81M | 0.03% | 638 |
|
Other funds holding VRTX
Wolverine Trading's VRTX Position: Q3 2025 in Review
Wolverine Trading increased its Vertex Pharmaceuticals (VRTX) stake by 16% in Q3 2025, buying an estimated $1.19M and bringing the position to 20,449 shares worth $8.08M. The position accounts for 0.01% of the portfolio, ranked #1054.
Wolverine Trading first reported a position in VRTX in Q3 2017 and has held it in 24 quarters since. The position peaked at $11.9M in Q4 2023. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.
- Wolverine Trading held 20,449 shares of Vertex Pharmaceuticals worth $8.08M as of Q3 2025.
- Wolverine Trading bought 2,854 Vertex Pharmaceuticals shares in Q3 2025, an estimated $1.19M.
- Vertex Pharmaceuticals made up 0.01% of Wolverine Trading's portfolio in Q3 2025, its #1054 holding.
- Wolverine Trading first reported a position in Vertex Pharmaceuticals in Q3 2017 and has held it in 24 quarters since.
- Wolverine Trading's Vertex Pharmaceuticals position peaked at $11.9M in Q4 2023.
- 1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.
Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.